Compile Data Set for Download or QSAR
Report error Found 350 Enz. Inhib. hit(s) with all data for entry = 1065
TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306556(US10144746, Compound 199 | (1R,8S)-N-[(4-carbamimi...)
Affinity DataIC50: 0.741nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306613(US10144746, Compound 256 | (1R,8S)-N-[(4-carbamimi...)
Affinity DataIC50: 0.759nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306637(US10144746, Compound 280 | (1R,8S)-N-[(4-carbamimi...)
Affinity DataIC50: 0.759nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306528(US10144746, Compound 170 | (+-)-N-[(4-carbamimidoy...)
Affinity DataIC50: 1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306535(US10144746, Compound 178 | (1R,8S)-N-[(6-amino-2,4...)
Affinity DataIC50: 1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306536(US10144746, Compound 179 | (1R,8S)-N-[(6-amino-2,4...)
Affinity DataIC50: 1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306538(US10144746, Compound 181 | (1R,8S)-N-[(6-amino-2,4...)
Affinity DataIC50: 1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306558(US10144746, Compound 201 | (1R,8S)-N-[(4- carbamim...)
Affinity DataIC50: 1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306559(US10144746, Compound 202 | (1R,8S)-N-[(4- carbamim...)
Affinity DataIC50: 1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306565(US10144746, Compound 208 | (1R,8S)-N-{[6-amino-2-m...)
Affinity DataIC50: 1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306581(US10144746, Compound 224 | (1R,8S)-N-[(6-amino-2,4...)
Affinity DataIC50: 1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306620(US10144746, Compound 263 | (1S,8R)-N-[(4-carbamimi...)
Affinity DataIC50: 1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306642(US10144746, Compound 285 | (1R,8S)-N-[(4-carbamimi...)
Affinity DataIC50: 1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306647(US10144746, Compound 290 | (1R,8S)-N-[(4-carbamimi...)
Affinity DataIC50: 1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306648(US10144746, Compound 291 | (1R,8S)-N-[(4-carbamimi...)
Affinity DataIC50: 1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306652(US10144746, Compound 296 | (1R,8S)-N-((4-carbamimi...)
Affinity DataIC50: 1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306658(US10144746, Compound 302 | (1R,8S)-N-[(4-carbamimi...)
Affinity DataIC50: 1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306662(US10144746, Compound 306 | (1R,8S)-N-[(4-carbamimi...)
Affinity DataIC50: 1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306663(US10144746, Compound 307 | (1S,8R)-N-[(4-carbamimi...)
Affinity DataIC50: 1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306668(US10144746, Compound 312 | (1S,8R)-N-[(4-carbamimi...)
Affinity DataIC50: 1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306685(US10144746, Compound 329 | (1R,8S)-N-[(4-carbamimi...)
Affinity DataIC50: 1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306686(US10144746, Compound 331 | (1R,8S)-N-[(4-carbamimi...)
Affinity DataIC50: 1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306703(US10144746, Compound 392 | (1S,8R)-N-[(4- carbamim...)
Affinity DataIC50: 1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306708(US10144746, Compound 400 | (1S,8R)-N-[(4-carbamimi...)
Affinity DataIC50: 1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306544(US10144746, Compound 187 | (1R,8S)-N-[(4- carbamim...)
Affinity DataIC50: 1.74nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306671(US10144746, Compound 315 | (+-)-N-[(4-carbamimidoy...)
Affinity DataIC50: 1.82nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306490((+-)-N-[(6-amino-4-methoxy-2- methylpyridin-3-yl)m...)
Affinity DataIC50: 2nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306492((+-)-N-[(6-amino-4-ethoxy-2- methylpyridin-3-yl)me...)
Affinity DataIC50: 2nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306574(US10144746, Compound 217 | (1S,8R)-N-[(4- carbamim...)
Affinity DataIC50: 2nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306593(US10144746, Compound 236 | (1S,8R)-N-[(4-carbamimi...)
Affinity DataIC50: 2nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306616(US10144746, Compound 259 | (1R,8S)-N-[(4- carbamim...)
Affinity DataIC50: 2nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306632(US10144746, Compound 275 | (1S,8R)-N-[(4-carbamimi...)
Affinity DataIC50: 2nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306654(US10144746, Compound 298 | (1R,8S)-N-[(4-carbamimi...)
Affinity DataIC50: 2nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306643(US10144746, Compound 286 | (1S,8R)-N-[(4-carbamimi...)
Affinity DataIC50: 2.45nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306678(US10144746, Compound 322 | (+-)-N-[(6-amino-2,4-di...)
Affinity DataIC50: 2.69nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306497((1R,8S)-N-[(6-amino-2,4- dimethylpyridin-3-yl)-met...)
Affinity DataIC50: 3.02nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306530(US10144746, Compound 173 | (+-)-N-{[6-amino-2-meth...)
Affinity DataIC50: 3.02nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306475((+-)-N-[(6-amino-4-methoxy- 2-methylpyridin-3-yl)m...)
Affinity DataIC50: 3.98nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306494((+-)-N-[(6-amino-4-ethyl-2- methylpyridin-3-yl)met...)
Affinity DataIC50: 3.98nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306546(US10144746, Compound 189 | (+-)-N-[(4-carbamimidoy...)
Affinity DataIC50: 4.57nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306371(US10144746, Compound 13 | (+-)-N-[(6-amino-2,4- di...)
Affinity DataIC50: 4.79nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306672(US10144746, Compound 316 | (+-)-N-[(4-carbamimidoy...)
Affinity DataIC50: 4.90nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306498((1R,8S)-N-[(6-amino-2,4- dimethylpyridin-3-yl)-met...)
Affinity DataIC50: 5.01nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306604(US10144746, Compound 247 | (1R,8S)-N-{[6-amino-2-m...)
Affinity DataIC50: 5.01nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306625(US10144746, Compound 268 | (1R,8S)-N-[(6-carbamimi...)
Affinity DataIC50: 5.01nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306691(US10144746, Compound 336 | (1S,8R)-N-[(4-carbamimi...)
Affinity DataIC50: 5.01nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306704(US10144746, Compound 396 | (+-)-N-[(4- carbamimido...)
Affinity DataIC50: 5.01nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306693(US10144746, Compound 338 | (1R,8S)-N-[(4-carbamimi...)
Affinity DataIC50: 5.89nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306426(US10144746, Compound 68 | BDBM306427 | (+-)-N-[(6-...)
Affinity DataIC50: 6.31nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Global Blood Therapeutics

US Patent
LigandPNGBDBM306641(US10144746, Compound 284 | (1S,8R)-N-[(4- carbamim...)
Affinity DataIC50: 6.31nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

Displayed 1 to 50 (of 350 total ) | Next | Last >>
Jump to: